The following results have been obtained from our experimental and clinical investigations of sulfamethoxazole (SMX) -trimethoprim (TMP) combination product.
1. Antibacterial activity :
The antibacterial activities of SMX were found to be significantly potentiated by the addition of TMP combined at a ratio of 20 : 1 (SMX-TMP) against coagulase-positive Staphylococci and Klebsiella strains. No potentiation was detectable in Pseudomonas strains tested.
2. Absorption :
Two healthy volunteers were given 4 tablets of SMX-TMP combination product (sulfamethoxazole 1600 mg + trimethoprim 320 mg) and blood levels of the 2 active principles were determined during the first and 6 th hour post-dose. Blood levels of free SMX ranged between 50-84 mcg/ml and those of trimethoprim between 3.5-5.3 mcg/ml.
3. Clinical results :
SMX-TMP combination product was given to 6 patients with respiratory tract infections (acute tonsillitis 1, acute pharyngitis 1, acute bronchitis 3, and bronchiectasis 1) and 4 patients with urinary tract infections (acute cystitis 3 and chronic pyelonephritis 1). The therapy was effective in 4 of the patients with respiratory tract infections and 2 of the patients with urinary tract infections. No untoward reaction has been encountered.
